Microrna-198 as a tumor suppressor in ovarian cancer
AssigneeBaylor College of Medicine
InventorsQizhi Yao, Christian Marin-Muller, Changyi Chen
Life of this patent
Estimating the term…
Loading patent…
AssigneeBaylor College of Medicine
InventorsQizhi Yao, Christian Marin-Muller, Changyi Chen
Estimating the term…
A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors, with important clinical implications. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, according to the present disclosure, MiR-198 replacement reverses tumorigenicity in vitro and in vivo. As such, an embodiment of the disclosure is a method of treating cancer in an individual, comprising the step of increasing the level of active microRNA-198 molecules in the pancreatic cancer tumor cells of the individual by an amount sufficient to cause an improvement in the pancreatic cancer in the individual
A method of treating cancer in an individual, comprising the step of delivering to the individual an effective amount of an agent that increases the level of microRNA-198 molecules in cancer cells of the individual.
A method of inhibiting proliferation and metastatic potential of at least one cancer cell in an individual, comprising delivering to the individual an effective amount of an composition which comprises an agent that increases the levels of microRNA-198 molecules in the cancer cell.
A kit for cancer treatment, said kit housed in a suitable container and comprising a first anti-cancer agent that increases the levels of active microRNA-198 molecules in a cell.
A composition comprising microRNA-198 and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.